Tumour dormancy and clinical implications in breast cancer

ecancermedicalscience

Volumn 7, Issue 1, 2013, Pages

  Gelao, L ^a   Criscitiello, C ^a   Fumagalli, L ^a   Locatelli, M ^a   Manunta, S ^a   Esposito, A ^a   Minchella, I ^a   Goldhirsch, A ^a   Curigliano, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Angiogenesis; Breast cancers; Immune surveillance; Microenvironment; Tumor dormancy

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; HEAT SHOCK PROTEIN 27; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE; MICRORNA; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER THERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CIRCULATING TUMOR CELL; ENDOPLASMIC RETICULUM; EPIGENETICS; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; IMMUNOSURVEILLANCE; METASTASIS; MICROMETASTASIS; NONHUMAN; PROTEIN SECRETION; REVIEW; RISK REDUCTION; TUMOR DORMANCY; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84878120607     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2013.320     Document Type: Review

References (77)

1. Willis RA (1952) The Spread of Tumors in the Human Body (London: Butterwoth and Co)
2. Uhr JW and Pantel K (2011) Controversies in clinical cancer dormancy Proc Natl Acad Sci USA 108 12396-400 DOI: 10.1073/pnas.1106613108 PMID: 21746894 PMCID: 3145712
3. Pantel K, Alix-Panabieres C and Riethdorf S (2009) Cancer micrometastases Nat Rev Clin Oncol 6 339-51 DOI: 10.1038/nrclinonc.2009.44 PMID: 19399023
4. Naumov GN, MacDonald IC, Weinmeister PM, et al (2002) Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy Cancer Res 62 2162-8 PMID: 11929839 (Pubitemid 34408466)
5. Naumov GN, MacDonald IC, Chambers AF and Groom AC (2001) Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol 11 271-6 DOI: 10.1006/scbi.2001.0382 PMID: 11513562 (Pubitemid 32799904)
6. Luzzi KJ, MacDonald IC, Schmidt EE, et al (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases Am J Pathol 153(3) 865-73 DOI: 10.1016/S0002-9440(10)65628-3 PMID: 9736035 (Pubitemid 28419039)
7. Holmgren L, O'Reilly MS and Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat Med 1 149-53 DOI: 10.1038/nm0295-149 PMID: 7585012
8. Klein CA, Schmidt-Kittler O, Schardt JA, et al (1999) Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells Proc Natl Acad Sci USA 96 4494-9 DOI: 10.1073/pnas.96.8.4494 PMID: 10200290 (Pubitemid 29190364)
9. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer Lancet 360 683-9 DOI: 10.1016/S0140-6736(02)09838-0 PMID: 12241875 (Pubitemid 35232337)
10. Schardt JA, Meyer M, Hartmann CH, et al (2005) Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer Cancer Cell 8(3):227-39 DOI: 10.1016/j.ccr.2005.08.003 PMID: 16169467 (Pubitemid 41317593)
11. Almog N, Ma L, Raychowdhury R, et al (2009) Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype Cancer Res 69 836-44 DOI: 10.1158/0008-5472.CAN-08-2590 PMID: 19176381
12. Steeg PS, Ouatas T, Halverson D, et al (2003) Metastasis suppressor genes: basic biology and potential clinical use Clin Breast Cancer 4(1) 51-62 DOI: 10.3816/CBC.2003.n.012 PMID: 12744759 (Pubitemid 36621624)
13. Almog N, Ma L, Schwager C, et al (2012) Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype PLoS One 7(8) e44001 DOI: 10.1371/journal.pone.0044001 PMCID: 3432069
14. Metge BJ, Frost AR, King JA, et al (2008) Epigenetic silencing contributes to the loss of BRMS 1 expression in breast cancer Clin Exp Met 25 753-63 DOI: 10.1007/s10585-008-9187-x
15. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 4-6 DOI: 10.1093/jnci/82.1.4 PMID: 1688381
16. Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 353-64 DOI: 10.1016/S0092- 8674(00)80108-7 PMID: 8756718 (Pubitemid 26272076)
17. Naumov GN, Bender E, Zurakowski D, et al (2006) A model of human tumor dormancy: an angiogenic switch from the non angiogenic phenotype J Natl Cancer Inst 98 316-25 DOI: 10.1093/jnci/djj068 PMID: 16507828 (Pubitemid 43338211)
18. Naumov GN, Akslen LA and Folkman J (2006) Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch Cell Cycle 5 1779-87 DOI: 10.4161/cc.5.16.3018 PMID: 16931911 (Pubitemid 44435320)
19. Hensel JA, Flaig WA and Theodorescu D (2012) Clinical opportunities and challenges in targeting tumour dormancy Nat Rev Clin Oncol 10(1) 41-51 DOI: 10.1038/nrclinonc.2012.207 PMID: 23183631
20. Folkman J, Watson K, Ingber D and Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia Nature 339 58-61 DOI: 10.1038/339058a0 PMID: 2469964 (Pubitemid 19115892)
21. Giuriato S, Ryeom S, Fan AC, et al (2006) Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch Proc Natl Acad Sci USA 103 16266-71 DOI: 10.1073/pnas.0608017103 PMID: 17056717 (Pubitemid 44715185)
22. Carmeliet P, Dor Y, Herbert JM, et al (1998) Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis Nature 394 485-90 DOI: 10.1038/28867 PMID: 9697772 (Pubitemid 28373960)
23. Hicklin DJ and Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23(5) 1011-27 DOI: 10.1200/JCO.2005.06.081 (Pubitemid 46202320)
24. Bergers G and Coussens LM (2000) Extrinsic regulators of epithelial tumor progression: metalloproteinases Curr Opin Genet Dev 10 120-7 DOI: 10.1016/S0959-437X(99)00043-X PMID: 10679388
25. Straume O, Shimamura T, Lampa MJ, et al (2012) Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer Proc Natl Acad Sci USA 109 8699-704 DOI: 10.1073/pnas.1017909109 PMID: 22589302 PMCID: 3365195
26. Dunn GP, Bruce AT, Ikeda H, et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape Nat Immunol 3 991-8 DOI: 10.1038/ni1102-991 PMID: 12407406 (Pubitemid 35363648)
27. Dunn GP, Old LJ and Schreiber RD (2004) The three Es of cancer immunoediting Annu Rev Immunol 22 329-60 DOI: 10.1146/annurev.immunol.22.012703. 104803 (Pubitemid 38680426)
28. Racila E, Scheuermann RH, Picker LJ, et al (1995) Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice J Exp Med 181 1539-50 DOI: 10.1084/jem.181.4.1539 PMID: 7535341
29. Teng MWL, Swann JB, Koebel CM, et al (2008) Immune-mediated dormancy: an equilibrium with cancer J Leukocyte Bio 84 988-993 DOI: 10.1189/jlb.1107774
30. Feuerer M, Rocha M, Bai L, et al (2001) Enrichment of memory T cells and other immunological changes in the bone marrow from untreated breast cancer patients Int J Cancer 92 96-105 DOI: 10.1002/1097-0215(200102)9999:9999〈;:: AID-IJC1152〉;3.0.CO;2-Q PMID: 11279612 (Pubitemid 32187038)
31. Ge W, Ma X, Li X, et al (2009) B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells Leuk Res 33 948-957 DOI: 10.1016/j.leukres.2009.01.007 PMID: 19233469
32. Farrar JD, Katz KH, Windsor J, et al (1999) Cancer dormancy. VII. A regulatory role for CD8π T cells and IFN-gamma in establishing and maintaining the tumor-dormant state J Immunol 162 2842-9 PMID: 10072532 (Pubitemid 29309310)
33. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy Nat Rev Immunol 6 295-307 DOI: 10.1038/nri1806 PMID: 16557261
34. Ribatti D and Crivellato E (2009) Immune cells and angiogenesis J Cell Mol Med 13 2822-33 DOI: 10.1111/j.1582-4934.2009.00810.x PMID: 19538473
35. Aguirre-Ghiso JA, Kovalski K and Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling J Cell Biol 147 89-104 DOI: 10.1083/jcb.147.1.89 PMID: 10508858
36. Bragado P, Sosa MS, Keely P, et al (2012) Microenvironments dictating tumor cell dormancy Recent Results Cancer Res 195 25-39 DOI: 10.1007/978-3-642-28160-0-3 PMID: 22527492 PMCID: 3516301
37. Wang Y, Klijn JG, Zhang Y, et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 671-9 PMID: 15721472 (Pubitemid 40260888)
38. Aguirre-Ghiso JA, Liu D, Mignatti A, et al (2001) Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo Mol Biol Cell 12 863-79 PMID: 11294892 PMCID: 32272
39. Allgayer H and Aguirre-Ghiso JA (2008) The urokinase receptor [u-PAR]-a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS 116 602-14 DOI: 10.1111/j.1600-0463.2008.00997.x PMID: 18834405
40. White DE, Kurpios NA, Zuo D, et al (2004) Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction Cancer Cell 6 159-70 DOI: 10.1016/j.ccr.2004.06.025 PMID: 15324699 (Pubitemid 39485688)
41. Kren A, Baeriswyl V, Lehembre F, et al (2007) Increased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function EMBO J 26 2832-42 DOI: 10.1038/sj.emboj.7601738 PMID: 17541405 (Pubitemid 46975787)
42. Aguirre-Ghiso JA, Estrada Y, Liu D and Ossowski L (2003) ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38 (SAPK) Cancer Res 63 1684-95 PMID: 12670923 (Pubitemid 36373662)
43. Schewe DM and Aguirre-Ghiso JA (2008) A TF6alpha-Rheb-mTOR signalling promotes survival of dormant tumor cells in vivo Proc Natl Acad Sci USA 105 10519-24 DOI: 10.1073/pnas.0800939105 PMID: 18650380
44. Houghton AM, Grisolano JL, Baumann ML, et al (2006) Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases Cancer Res 66 6149-55 DOI: 10.1158/0008-5472.CAN-04-0297 PMID: 16778188
45. Tlsty TD and Coussens LM (2006) Tumor stroma and regulation of cancer development Annu Rev Pathol 1 119-50 DOI: 10.1146/annurev.pathol.1.110304.100224
46. Xenidis N, Ignatiadis M, Apostolaki S, et al (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer J Clin Oncol 27 2177-84 DOI: 10.1200/JCO.2008.18.0497 PMID: 19332733
47. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al (2002) Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance J Clin Oncol 20 3404-12 DOI: 10.1200/JCO.2002.08.135 PMID: 12177100
48. Saloustros E, Perraki M, Apostolaki S, et al (2011) Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse Breast Cancer Res 13(3) R60 DOI: 10.1186/bcr2897 PMCID: 3218949
49. Janni W, Vogl FD, Wiedswang G, et al (2011) Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse - a european pooled analysis Clin Cancer Res 17(9) 2967-76 DOI: 10.1158/1078-0432.CCR-10-2515 PMID: 21415211
50. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al (2003) Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA 100 3983-8 DOI: 10.1073/pnas.0530291100 PMID: 12629218 PMCID: 153034 (Pubitemid 36418143)
51. Enderling H, Hlatky L and Hahnfeldt P (2009) Migration rules: tumours are conglomerates of self metastases Br J Cancer 100 1917-25 DOI: 10.1038/sj.bjc.6605071 PMID: 19455139 PMCID: 2714240
52. Li F, Tiede B, Massague J and Kang Y (2007) Beyond tumorigenesis: cancer stem cells in metastasis Cell Res 17 3-14 DOI: 10.1038/sj.cr.7310118 (Pubitemid 46096419)
53. Reya T, Morrison SJ, Clarke MF and Weissman IL (2001) Stem cells, cancer, and cancer stem cells Nature 414 105-11 DOI: 10.1038/35102167 PMID: 11689955 (Pubitemid 33041634)
54. Wang S, Yang D and Lippman ME (2003) Targeting Bcl-2 and Bcl-XL with non peptidic small-molecule antagonists Semin Oncol 30 133-42 DOI: 10.1053/j.seminoncol.2003.08.015 PMID: 14613034 (Pubitemid 37433404)
55. Liu S, Dontu G, Mantle ID, et al (2006) Hedgehog signalling and BMi-1 regulate self-renewal of normal and malignant human mammary stem cells Cancer Res 66 6063-71 DOI: 10.1158/0008-5472.CAN-06-0054 PMID: 16778178
56. Li L and Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters Cancer Res 66 4553-4557 DOI: 10.1158/0008-5472.CAN-05-3986 PMID: 16651403
57. Lou H and Dean M (2007) Targeted therapy for cancer stem cells: the patched pathway and ABC transporters Oncogene 26 1357-60 DOI: 10.1038/sj.onc.1210200 PMID: 17322922 (Pubitemid 46328461)
58. Singh A and Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer Oncogene 29 4741-51 DOI: 10.1038/onc.2010.215 PMID: 20531305
59. Almog N (2010) Molecular mechanisms underlying tumor dormancy Cancer Lett 294(2) 139-46 DOI: 10.1016/j.canlet.2010.03.004 PMID: 20363069
60. Watnick RS, Cheng YN, Rangarajan A, et al (2003) Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis Cancer Cell 3 219-31 DOI: 10.1016/S1535-6108(03)00030-8 PMID: 12676581 (Pubitemid 37443878)
61. Kim RS, Avivar-Valderas A, Estrada Y, Bragado P, et al (2012) Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer PLoS One 7(4) e35569 DOI: 10.1371/journal.pone.0035569 PMCID: 3329481
62. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-717 PMID: 15894097
63. Cervi D, Yip TT, Bhattacharya N, et al (2008) Platelet-associated PF-4 as a biomarker of early tumor growth Blood 111 1201-7 DOI: 10.1182/blood-2007-04- 084798 (Pubitemid 351213401)
64. Carlsson A, Wingren C, Kristensson M, et al (2011) Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases Proc Natl Acad Sci USA 108 14252-7 DOI: 10.1073/pnas. 1103125108 PMID: 21844363 PMCID: 3161545
65. Naumov CN, Townson JL, MacDonald IC, et al (2003) Ineffectiveness of doxorubicin treatment on solitary dormant mammary cancer cells or late-developing metastases Breast Cancer Res Treat 82(3) 199-206 DOI: 10.1023/B:BREA.0000004377.12288.3c (Pubitemid 37521976)
66. Andre T, Van Cutsem E, Schmoll H, et al (2011) A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): subgroup analyses from the AVANT trial J Clin Oncol 29 PMID: 21343554
67. Allegra CJ, Yothers GA, O'Connell MJ, et al (2011) Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer J Clin Oncol 29 DOI: 10.1200/JCO.2010.30.0855 PMID: 21969501 PMCID: 3188282
68. Paget S (1889) The distribution of secondary growths in cancer of the breast Lancet 1 571-3 DOI: 10.1016/S0140-6736(00)49915-0
69. Roodman GD (2004) Mechanisms of bone metastasis N Engl J Med 350(16) 1655-64 DOI: 10.1056/NEJMra030831 PMID: 15084698
70. Costa L, Harper P, Coleman RE and Lipton A (2011) Anticancer evidence for zoledronic acid across the cancer continuum Crit Rev Oncol Hematol 77(11) S31-7 DOI: 10.1016/S1040-8428(11)70006-3
71. Gnant M, Mlineritsch B, Schippinger W, et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Eng J Med 360(7) 679-91 DOI: 10.1056/NEJMoa0806285
72. Coleman RE, Marshall H, Cameron D, et al on behalf of the AZURE Investigators (2011) Breast cancer adjuvant therapy with zoledronic acid N Engl J Med 365(15) 1396-405 DOI: 10.1056/NEJMoa1105195 PMID: 21995387
73. Study to determine treatment effects of denosumab in patients with breast cancer receiving aromatase inhibitor therapy ClinicalTrials.gov. NCT00556374
74. Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE) ClinicalTrials.gov. NCT01077154
75. Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade Nat Rev Cancer 4 448-56 DOI: 10.1038/nrc1370 (Pubitemid 38745530)
76. Goss PE and Chambers AF (2010) Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 10(12) 871-7 DOI: 10.1038/nrc2933 PMID: 21048784
77. Goss PE, Ingle JN, Martino S, et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1793-802 DOI: 10.1056/NEJMoa032312 PMID: 14551341 (Pubitemid 37362955)